COMBIFRINIL Tablet

In cases of hyper-sensitivity to pyrantelum or to any other substance in Combifrinil.

Secondary effects may sometimes occur in the form of gastrointestinal disturbances, e.g. anorexia, abdominal cramps, diarrhoea, nausea or vomiting.

Exceptionally: headache, dizziness, drowsiness, insomnia, rash.

The mechanism underlying the action of piperazine is antagonistic to that of Pyrantel, and therefore these two drugs should not be administered simultaneously.

Category B.

No controlled study is available on animals and pregnant women, therefore, this medicine should be taken by pregnant women only if the potential advantage is higher than the risk for the foetus.

We do not know, if the Pyrantelum passes the barrier of the parental milk. Therefore this medicine should be breast-feeding mothers only in cases of absolute necessity.

Administer with caution to patients suffering from a liver dysfunction. A minimal and momentary increase in SGOT’s has rarely been observed.

Paediatrics: Combifrinil should not be administered to children under the age of 6 months, because the product has not been studied on children at this age.

Pyrantel, the active ingredient of Combifrinil, paralyses by means of neuromuscular blocking the mature and immature forms of sensitive worms. Combifrinil is suited for the single-dose treatment of oxyuris, ascaris and Ancylostoma. Due to its paralysing effect, ascaris worms are eliminated without stimulation of worm migration.